Hims & Hers CEO Pushes Back on FTC Lawsuit Over GLP-1 Drugs

Hims & Hers CEO Andrew Dudum is mounting a public defense of his company after the Federal Trade Commission filed a lawsuit targeting the telehealth platform, arguing that regulators have a flawed understanding of how the business actually functions. Speaking directly to CNBC, Dudum framed the legal action as a case of institutional misreading rather than genuine wrongdoing — a posture that signals the company intends to fight the charges rather than seek a quick settlement.

At the center of the dispute are compounded GLP-1 drugs, the class of weight-loss and diabetes medications that has become one of the most commercially significant pharmaceutical categories in recent memory. Compounded versions — typically mixed by specialty pharmacies rather than brand-name manufacturers — have proliferated as demand for drugs like semaglutide has outstripped supply. Hims & Hers has positioned itself as a convenient access point for these alternatives, but that strategy has drawn regulatory scrutiny over how such products are marketed and sold to consumers.

Read more Costco Partners With SCAN Group to Offer Medicare Advantage Plans →

Dudum's comments to CNBC also touched on the company's use of artificial intelligence, underscoring how Hims & Hers views technology as central to its care delivery model. The dual mention of AI and compounded drugs in the same conversation reflects a broader strategic bet: that combining digital convenience with lower-cost medication alternatives can carve out durable market share in a crowded telehealth landscape — even as that bet invites friction with federal watchdogs.

The FTC's involvement marks an escalation in regulatory attention toward the compounded GLP-1 market more broadly, and the outcome of this case could set precedents for how other telehealth companies advertise and distribute similar products. For investors and industry observers, Dudum's willingness to engage the press directly — rather than letting lawyers do the talking — suggests Hims & Hers sees reputational positioning as just as important as the legal battle itself.

Continue reading at US Top News and Analysis